Literature DB >> 31860298

Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.

Hao Chen1, Shanshan Deng1, Yuxi Wang2, Najah Albadari1, Gyanendra Kumar3, Dejian Ma1, Weimin Li2, Stephen W White3, Duane D Miller1, Wei Li1.   

Abstract

We recently reported the crystal structure of tubulin in complex with a colchicine binding site inhibitor (CBSI), ABI-231, having 2-aryl-4-benzoyl-imidazole (ABI). Based on this and additional crystal structures, here we report the structure-activity relationship study of a novel series of pyridine analogues of ABI-231, with compound 4v being the most potent one (average IC50 ∼ 1.8 nM) against a panel of cancer cell lines. We determined the crystal structures of another potent CBSI ABI-274 and 4v in complex with tubulin and confirmed their direct binding at the colchicine site. 4v inhibited tubulin polymerization, strongly suppressed A375 melanoma tumor growth, induced tumor necrosis, disrupted tumor angiogenesis, and led to tumor cell apoptosis in vivo. Collectively, these studies suggest that 4v represents a promising new generation of tubulin inhibitors.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31860298     DOI: 10.1021/acs.jmedchem.9b01815

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective.

Authors:  Jiaxing Wang; Duane D Miller; Wei Li
Journal:  Drug Discov Today       Date:  2021-12-08       Impact factor: 7.851

2.  X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor.

Authors:  Souvik Banerjee; Foyez Mahmud; Shanshan Deng; Lingling Ma; Mi-Kyung Yun; Sayo O Fakayode; Kinsie E Arnst; Lei Yang; Hao Chen; Zhongzhi Wu; Pradeep B Lukka; Keyur Parmar; Bernd Meibohm; Stephen W White; Yuxi Wang; Wei Li; Duane D Miller
Journal:  J Med Chem       Date:  2021-08-18       Impact factor: 8.039

3.  Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents.

Authors:  Hao Chen; Shanshan Deng; Najah Albadari; Mi-Kyung Yun; Sicheng Zhang; Yong Li; Dejian Ma; Deanna N Parke; Lei Yang; Tiffany N Seagroves; Stephen W White; Duane D Miller; Wei Li
Journal:  J Med Chem       Date:  2021-08-11       Impact factor: 8.039

4.  Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer.

Authors:  Shanshan Deng; Raisa I Krutilina; Kelli L Hartman; Hao Chen; Deanna N Parke; Rui Wang; Foyez Mahmud; Dejian Ma; Pradeep B Lukka; Bernd Meibohm; Tiffany N Seagroves; Duane D Miller; Wei Li
Journal:  Mol Cancer Ther       Date:  2022-07-05       Impact factor: 6.009

5.  Discovery of N-(3,4-Dimethylphenyl)-4-(4-isobutyrylphenyl)-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinoline-8-sulfonamide as a Potent Dual MDM2/XIAP Inhibitor.

Authors:  Zhongzhi Wu; Lubing Gu; Sicheng Zhang; Tao Liu; Pradeep B Lukka; Bernd Meibohm; John C Bollinger; Muxiang Zhou; Wei Li
Journal:  J Med Chem       Date:  2021-02-08       Impact factor: 8.039

6.  The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.

Authors:  Hongmei Cui; Qinghui Wang; Duane D Miller; Wei Li
Journal:  Front Pharmacol       Date:  2021-03-25       Impact factor: 5.810

7.  Tubulin Inhibitors: A Chemoinformatic Analysis Using Cell-Based Data.

Authors:  Edgar López-López; Carlos M Cerda-García-Rojas; José L Medina-Franco
Journal:  Molecules       Date:  2021-04-24       Impact factor: 4.411

8.  Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer.

Authors:  Rajan Sharma Bhattarai; Virender Kumar; Svetlana Romanova; Jitender Bariwal; Hao Chen; Shanshan Deng; Vijaya R Bhatt; Tatiana Bronich; Wei Li; Ram I Mahato
Journal:  J Control Release       Date:  2020-09-30       Impact factor: 9.776

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.